|
Dynamics of mutant BRAF V600E in free circulating DNA (fcDNA) of non-melanoma cancer patients (pts) in response to treatment with BRAF and MEK/EGFR inhibitors. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; Pfizer; Roche Pharma AG |
Consulting or Advisory Role - Pfizer |
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
Research Funding - Roche/Genentech |
|
|
No Relationships to Disclose |